Sol-Gel Technologies is an experienced dermatology company developing advanced treatments for patients with rare skin conditions.

2024年9月30日 · Sol-Gel reported a net loss of $0.4 million for the third quarter of 2024 and loss of $0.01 per basic and diluted share, compared to a net loss of $5.7 million and a loss of $0.21 per basic and diluted share for the same period in 2023.

2024年5月16日 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.

2024年7月12日 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults.

Sol-Gel Technologies announces FDA approval of TWYNEO®. Sol-gel.com. July 27, 2021. Accessed August 22, 2023. https://ir.sol-gel.com/news-releases/news-release-details/sol-gel-technologies-announces-fda-approval-twyneor.

2023年1月27日 · Patidegib, an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA; Phase 3 study expected to initiate in the second half of 2023, with results expected by the end of 2025

2021年6月28日 · Sol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected to be launched; Our proof-of-concept study for SGT-210 (erlotinib gel) in palmoplantar keratoderma patients has been completed and indicated a possible modest improvement

2024年5月21日 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. both drugs are exclusively licensed to and commercialized by Galderma in the US; and are ...

2021年7月27日 · Sol‑Gel leverages its proprietary microencapsulation technology platform for TWYNEO, which is approved for the treatment of acne vulgaris in adults and pediatric patients 9 years of age and older; and EPSOLAY, under investigation for the treatment of inflammatory lesions of rosacea with an NDA filed with the FDA and a PDUFA goal date that was ...

Sol-Gel Technologies is an experienced dermatology company that is leveraging innovative approaches to develop advanced treatments for patients with severe skin conditions.